TransMedics, a firm specializing in organ preservation technology, secures $36m

TransMedics Inc., an Andover-based firm focused on organ preservation technology, announced the closing of a $36 million financing round led by Abrams Capital with the participation of existing investors including Flagship Ventures, Hercules Technology Growth Capital, and Kleiner Perkins Caufield & Byers.

‘‘TransMedics is revolutionizing the field of solid organ preservation for transplantation and is well positioned to become the worldwide market leader,’’ Abrams Capital managing member David Abrams said in a statement.


Dr. Waleed Hassanein, president and chief executive of TransMedics, added, ‘‘This financing enables us to complete our heart and lung FDA pivotal trials and expand our global commercial activities.’’

According to the company, its portable preservation technology maintains donor organs in a near-physiologic and functioning condition from donor to transplant recipient. 

Abrams Capital is a Boston-based investment firm that currently manages $5.7 billion.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
We hope you've enjoyed your free articles.
Continue reading by subscribing to for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of